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Urinary excretion of platelet activating factor in patients with immune-
mediated glomerulonephritls. We have investigated whether human
immune-mediated glomerulonephritis is associated with changes in
platelet activating factor (PAF) biosynthesis. Urinary PAF, taken as a
marker of its renal synthesis, was significantly higher in patients with
membranous nephropathy (N = 9) than in healthy controls (N = 8).
This was not due to a lower degradation of PAF since urinary
acetylhydrolase activity was comparable in patients and controls. A
significant positive correlation between urinary excretion of PAF and
proteinuria was observed. PAF generation was comparable in polymor-
phonuclear cells isolated from patients with membranous nephropathy
and controls. PAF levels in blood from patients with membranous
nephropathy were significantly lower than in controls, suggesting that
the excessive generation of PAF is confined to the kidney. The results
document that signs of renal disease activity in human membranous
nephropathy are associated with an excessive renal synthesis of PAF.
Platelet activating factor (PAF) is a potent mediator of
inflammation produced by leukocytes, macrophages and gb-
merular cells upon immunologic and nonimmunologic stimula-
tion [1]. Experimental evidence is available suggesting that PAF
may participate in renal immune injury by favoring immune
complex deposition [2] and increasing gbomerular permeability
to proteins [3]. The most important studies in this context are
those showing that isolated glomeruli from experimental ani-
mals with various nephropathies synthesize significantly more
PAF than normal glomeruli [4, 5] and that there is an associa-
tion between the release of PAF from inflammatory cells and
the localization of glomerular immune material [2]. Previous
studies in experimental lupus nephritis have also documented
an increased renal synthesis and urinary excretion of PAF
which correlated with the severity of proteinuria [6, 7]. How-
ever, the definitive proof for the role of PAF in experimental
gbomerulonephritis has only been obtained by pharmacological
manipulation of PAF activity at receptor level. In this context
we and others have documented that both in rabbits with
nephrotoxic nephritis [8] and in the lupus mice model [6, 7], a
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specific PAF receptor antagonist attenuated glomerular dam-
age, reduced proteinuria and improved renal function.
Altogether the above studies appear to consistently indicate
that PAF is likely an important mediator of renal damage.
Surprisingly, almost no studies have been done in human beings
so far. A notable exception is the preliminary observation of
Sanchez-Crespo and coworkers [9] that in a patient with sys-
temic lupus erythematosus and glomerulopathy a significantly
greater PAF-related bioactivity was detectable in the urine as
compared to normal urine.
The present study was performed in patients with membra-
nous nephropathy with the aim to establish whether in humans
immune complex formation and altered permeability to proteins
were associated with changes in the urinary excretion of PAF,
which may be taken as a marker of its renal synthesis in vivo, as
suggested by recent studies in experimental animals [10, 11].
Methods
Nine patients (5 males and 4 females, 29 to 69 years of age)
with membranous nephropathy who had been referred to the
Division of Nephrobogy and Dialysis of the Ospedali Riuniti di
Bergamo were studied. Diagnosis of membranous nephropathy
was ascertained by clinical and histological evaluation. All
patients had proteinuria ranging from 1.86 to 10.3 glday. All
patients but one had creatinine clearance above 80 ml per
minute. Histological evaluation was assessed by light and
electron microscopy. A control group of eight age-matched
subjects (3 males and 5 females) without history of renal disease
were studied simultaneously. Patients and controls did not
receive any treatment during the study.
Urine was collected over 12 hours, 5 ml aliquots were
immediately used for acetyihydrolase activity assessment and
the remaining sample was frozen until PAF, j32-microglobulin
and protein excretion were assessed.
For PAF measurement, urine samples (10 ml) were added
with 1.5 volumes of methanol, gently mixed and centrifuged.
Supernatant was then extracted according to the Bligh and Dyer
procedure [12] and further purified by a silicic acid column as
previously described [11].
Blood (24 ml) was directly collected in 3 volumes of ice-cold
methanol and centrifuged at 3000 x g for 20 minutes at 0°C. The
upper layer was then extracted according to the Bligh and Dyer
procedure [12] and further purified by silica disposable column
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(Sep-pak, Millipore, Milford, Massachusetts, USA) according
to the method of Yamada et a! [13].
Polymorphonuclear cells (PMNs) were isolated from hepa-
rinized (10 U/mi) venous blood as previously described [14].
The purified cell preparation, containing about 95% PMNs, was
finally suspended at 2 x 106 cells/mi in Hank's balanced
solution containing Mg and 0.25% BSA. Cell viabil-
ity, measured by Trypan blue exclusion, was >98%. Aiiquots (1
ml each) of PMN suspension were incubated at 37°C for 30
minutes in the presence of calcium ionophore A23 187 (10 M)
or its vehicle (0.1% DMSO). At the end of the incubation,
samples were added twice with 2 volumes of acidified methanol,
gently mixed and centrifuged. Supernatant was then extracted
according to the Bligh and Dyer procedure [12] and purified by
a silicic acid column, as previously described [11]. One hundred
microliters of serial dilutions of each sample were assayed in
duplicate for PAF using a commercial radioimmunoassay (RIA)
kit (New England Nuclear, Boston, Massachusetts, USA).
Good linearity was observed between concentrations from 10 to
100 pg/tube. The lowest detectable concentration that could be
measured with 95% confidence was 30 pg/tube. PAF levels for
all samples were corrected for the recovery which averaged
60% (range 50 to 80%) as determined by addition of trace
amounts of [3H]PAF ([1',2'-3H]alkyl, 59.9 Ci/mmol, New En-
gland Nuclear) to all samples before extraction. PAF recovery
was comparable in samples from patients and controls. The
intra- and inter-assay coefficient of variation were 10% and
12%, respectively. PAF antibody recognizes both C18 and C16
PAF alkyl species. In order to verify the accuracy of the values
obtained by RIA measurement, the amount of PAF produced
by PMNs from four patients and three controls was also
assessed by gas chromatography-mass spectrometry. To this
purpose at the end of the incubation period 5 ng of deuterated
PAF (D3) were added to the samples which were extracted and
purified as above. C16-PAF, which is the most abundant PAF
alkyl species in PMNs [15], was analyzed by gas chromatogra-
phy-negative ion chemical ionization mass spectrometry (GC-
NICIMS) [11]. A highly significant correlation was found be-
tween RIA and GC-NICIMS values both for unstimulated and
A23187 stimulated samples (r = 0.98, P < 0.001, y = l.326x +
0.937; Fig. 1).
To evaluate urinary acetyihydrolase activity, two aliquots of
urine (5 ml each) from patients and controls were added
with i-hexadecyt-2-[3H]acetyl-sn-glycero-3-phosphocholine ([3H]
acetyl-PAF, 0.2 nM, 10 Cilmmol, New England Nuclear) and
incubated for two hours at 37°C and room temperature, respec-
tively. At the end of the incubation sodium bicarbonate solution
was added to correct the pH to 6.5 to 7, thereafter lipids were
extracted according to the method of Bligh and Dyer [12]. The
[3H]acetate recovered in the water/methanol phase was deter-
mined by liquid scintillation counting. For each set of assays, a
sample was heat-inactivated and the radioactivity recovered in the
water/methanol phase (<1%) subtracted as the blank control. To
assess the efficiency of the extraction procedure, [3H]acetyl-PAF
was hydrolyzed to [3H]acetate with 0.5 N NaOH at 50°C for 30
minutes, thereafter the sample was neutralized with HCI and
extracted by Bligh and Dyer [12]. The radioactivity recovered in
the water/methanol phase was about 97%. To exclude the possi-
bility that urinary acetylhydrolase might be degraded during the 12
hour collection, in some subjects (N 3) PAF acetylhydrolase
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Fig. 2. Urinary excretion rate of PAF (nglhr) and urinary PAF acetyl-
hydrolase activity (fmol/hr/ml) in patients with membranous nephrop-
athy (; N = 9) and in controls (El; N = 8). Urinary PAF was measured
by RIA. Acetylhydrolase activity was evaluated as [3H]acetate formed
from [3H]acetyl-PAF after a two hour incubation at 37°C. Data are
mean SD. *P < 0.01 vs. controls.
activity was measured both in freshly collected urine and in urine
stored at room temperature for 12 hours. The enzymatic activity
recovered in urine stored for 12 hours at room temperature was
about 75% than that found in freshly collected urine. Urinary
/32-microglobulin was evaluated by enzyme-immunoassay using a
commercial kit (Abbott Diagnostics, Chicago, Illinois, USA).
Proteinuria and urinary creatinine were assessed by routine labo-
ratory methods.
Results are expressed as mean SD. Data were analyzed by
the Mann-Whitney test, Spearman correlation test or linear
regression where appropriate. P values <0.05 were considered
to be significant.
Results
Urinary excretion of PAF was significantly higher in patients
with membranous nephropathy as compared to healthy subjects
(6.27 2.76 vs. 2.61 0.72 ng/hr, P < 0.01; Fig. 2). Similar
results were obtained when data were corrected for urinary
creatinine (0.106 0.048 vs. 0.045 0.017 ng/mg creatinine, P
<0.02).
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Fig. 1. Linear regression analysis of PAF content in PMNs from
patients (N = 4) and controls (N = 3) measured by GC-NICIMS
against ir-PAF content in PMNs measured by radioimmunoassay
(RIA). Data are from both unstimulated and A23187 stimulated sam-
ples. r = 0.98; P < 0.001.
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membranous nephropathy were the consequences of a reduced
0 tubular reabsorption.As for the origin of urinary PAF, studies in experimental
animals documented that circulating PAF is excreted in negli-
gible amounts in the urine [101 while all the so-far available
0 evidence concurs to indicate that, at least in animals, urinary
PAF is a function of its formation within the kidney [10, 11].
00 0 With the limitation of the above statements, the present study
may be taken as the first in vivo evidence for an excessive renal
0 0 formation of PAF in a human disease. Consistent with this0 0 interpretation are findings that circulating levels of PAF in
patients with membranous nephropathy are even lower than
• ___,_o,,___Q healthy controls, suggesting that the excessive generation of
0 2 4 6 8 10 12 14 PAF is confined to the kidney. Lower levels of PAF in bloodfrom patients with membranous nephropathy might be due to
increased degradation of the phospholipid rather than to re-
duced synthesis, since PAF generation from isolated PMNs was
comparable in patients and controls.
Since PAF increases vascular permeability [17] and induces
release of cationic proteins from polymorphs and platelets [18],
it is tempting to speculate that the increased renal synthesis of
PAF contributes to the localization of immune complexes in
membranous nephropathy. This interpretation is consistent
with animal studies showing that immune complexes deposition
at glomerular level are favored when vascular permeability is
enhanced and glomerular capillary anionic sites are neutralized
[2, 19].
The highly significant correlation between PAP urinary ex-
cretion rate and proteinuria would also suggest that PAF plays
a role in the abnormal permeability to proteins that follows
glomerular immune complex formation in experimental and
human nephropathies. Thus, Camussi et al [18] have reported
that infusion of PAF in normal rabbits is associated with
transient proteinuria coincident with the deposition of cell-
derived cationic proteins in the glomerular capillary wall. On
the other hand, isolated perfused kidney studies [31 documented
that PAF must not necessarily activate circulating cells in order
to increase the passage of macromolecules through the glomer-
ular barrier. Finally, recent evidence is available that PAF
alters glomerular size-selective properties by selectively en-
hancing transmural passage of large nearly impermeant dex-
trans [20]. This phenomenon requires the interaction with a
specific receptor and is probably mediated by an increase in
intracellular calcium [20]. In conclusion, the present study has
documented that signs of renal disease activity in human
membranous nephropathy are associated with an excessive
renal synthesis of PAF. This would implicate that molecules
which antagonize PAF receptor, already effective in experimen-
tal glomerulonephritis, may hopefully play a role in the future in
Discussion the treatment of glomerulopathies.
The first finding of the present study was that the excretion of
PAF increased significantly in the urine of patients with mem-
branous nephropathy and proteinuria as compared to age- and
sex-matched healthy controls. The possibility that high urinary
PAF levels were merely the consequence of a lower degrada-
tion of the phospholipid in patients' urine was ruled out by
findings of comparable urinary PAF acetylhydrolase activity in
patients and controls. Furthermore, the absence of a correlation
between urinary PAF and j32-microglobulin would exclude the
possibility that the high urinary PAP levels in patients with
C
0)00
12
10
8
6
4
2
0
Urinary PAF, ng/hr
Fig. 3. Correlation between individual urinary excretion values of PAF
and proteinuria in patients with membranous nephropathy and con-
trols. rho = 0.686, P < 0.05.
Since urinary PAF acetylhydrolase can degrade PAF by
hydrolysis of the sn-2 acetyl moiety [16], the possibility that
increased urinary PAP in patients with membranous nephrop-
athy was due to lower activity of the urinary PAF acetylhydro-
lase with respect to that of controls was investigated. Urinary
acetylhydrolase activity was comparable in patients and con-
trols both when it was measured at 37°C (17.88 11.27 vs.
14.66 12.5 fmollhr!ml; Fig. 2) and at room temperature (5,26
3.03 vs. 3.99 3.03 fmollhr/ml).
A positive correlation, shown in Figure 3, was found between
PAF urinary excretion rate and proteinuria (rho = 0.686, P <
0.05, Spearman test). By contrast, PAF urinary excretion rate
did not correlate with urinary f32-microglobulin (rho = 0.38).
Blood PAF levels were undetectable in five out of nine
patients and two out of eight controls. Attributing an arbitrary
value equal to the detection limit of the assay (7.5 pg/ml) to
those cases with undetectable PAF blood level, mean values of
the total population averaged 13.94 11.4 pg/ml in patients and
44.6 36.5 pg/mI in controls, a difference which was statisti-
cally significant (P < 0.05).
The synthesis of PAF by circulating PMNs was also evalu-
ated after a 30 minute incubation in the absence or presence of
Ca ionophore A23187. PAF production by PMNs from
patients with membranous nephropathy was not significantly
different from values of controls either as for spontaneous
release (1.03 0.77 vs. 0.51 0.26 ng/106 cells) or A23187
induced synthesis (40.82 8.39 vs. 52.15 27.42 ng/l06 cells).
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